Thermo Fisher Scientific Continues Expansion
Thermo Fisher Scientific (Massachusetts, USA) celebrated the opening of its new single-use technology manufacturing site in Ogden, Utah, USA, and announced a $97 million expansion to its bioanalytical laboratory operations across three new locations in Virginia’s Greater Richmond region. The state‑of-the-art facility in Utah creates additional capacity for the development of new vaccines and therapies.
The Ogden site is a 55,000-square-ft facility that will manufacture customizable bioprocess container (BPC) systems. These BPCs are used for the delivery, processing, separation, storage, and transportation of critical liquids used in the production of biologics, vaccines, and cell and gene therapies. The site has hired more than 300 employees and has the potential to employ up to 450 people, adding to the 2000 strong workforce the company has across the state of Utah and establishing a critical hub for bioprocessing.
“The Ogden facility further strengthens our global manufacturing network, which has been growing to meet increasing demand for single-use consumables and critical raw materials,” said Mitch Kennedy, President, Single-Use Technologies, Thermo Fisher Scientific. “This new facility expands our presence in Utah and locating here gives us the ability to work closely with our Logan site, providing access to a talented workforce that is ideal for manufacturing.”
In Virginia, the existing laboratory services operation there comprises more than 300,000-square-ft, making it one of the largest laboratories of its kind in the world; it employs more than 1200 professionals. Thermo Fisher acquired the laboratories with the purchase of PPD, Inc., in December 2021. The expansion is part of Thermo Fisher’s $650 million multi-year investment, announced last year, to help ensure flexible, scalable, and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19. Longer term, the company plans to continue to invest in and connect the capabilities across the combined company. The bulk of the expansion will occur in immunochemistry and chromatography functions, as well as subsequent enhancements in biomarker and vaccine sciences. Two new bioanalytical laboratories will be established in Virginia’s Henrico County, and a third will be established at the VA Bio+Tech Park in the city of Richmond.
“Worldwide, we continue to expand our lab capacity to provide customers with high-quality bioanalytical lab services to advance their clinical research programmes,” said David M. Johnston, Ph.D., Senior VP and President, Clinical Research, Thermo Fisher Scientific. “These services are vital for drug development, as approximately 70% of data generated in clinical trials comes from analytical laboratory testing. We’re pleased to extend our partnership with Virginia, Henrico County, and the city of Richmond to continue our efforts to help customers deliver life-changing therapies to patients in need.”
For more information, please visit: https://corporate.thermofisher.com
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
